<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04935086</url>
  </required_header>
  <id_info>
    <org_study_id>KY-2020388</org_study_id>
    <nct_id>NCT04935086</nct_id>
  </id_info>
  <brief_title>Risk Factors for Predictors of MACEs After RA-CABG</brief_title>
  <official_title>Risk Factors for Predictors of Major Adverse Cardiovascular Events After Coronary Artery Bypass Using Radial Artery Grafts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As the secondary choice of artery grafts, radial artery is more and more used to achieve&#xD;
      multiple arterial revascularization in CABG. Risk factors for predictors of major&#xD;
      cardiovascular adverse events (MACE) after CABG using radial-artery grafts (RA-CABG),&#xD;
      however, remain uncertain. This case-control study aims to identify the baseline predictors&#xD;
      of MACE after RA-CABG.&#xD;
&#xD;
      We will collect the baseline characteristics and perioperative data of patients underwent&#xD;
      RA-CABG from Jan. 2009 to Dec. 2019 in our single center. By reviewing the latest follow-up&#xD;
      records, we will examine the correlation between the baseline characteristics and clinical&#xD;
      outcomes (MACEs), then identify the independent risk factors for predictors of MACEs after&#xD;
      RA-CABG.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>7-day MACE-4</measure>
    <time_frame>7 days post-CABG</time_frame>
    <description>a composite of all-cause death, myocardial infraction, stroke and repeat revascularization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>30-day MACE-4</measure>
    <time_frame>30 days post-CABG</time_frame>
    <description>a composite of all-cause death, myocardial infraction, stroke and repeat revascularization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1-year MACE-4</measure>
    <time_frame>1 year post-CABG</time_frame>
    <description>a composite of all-cause death, myocardial infraction, stroke and repeat revascularization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3-year MACE-4</measure>
    <time_frame>3 years post-CABG</time_frame>
    <description>a composite of all-cause death, myocardial infraction, stroke and repeat revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE-3</measure>
    <time_frame>7 days, 30 days, 1 year, and 3 years post-CABG</time_frame>
    <description>a composite of CV-death, myocardial infraction and stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>7 days, 30 days, 1 year, and 3 years post-CABG</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CV-death</measure>
    <time_frame>7 days, 30 days, 1 year, and 3 years post-CABG</time_frame>
    <description>Including death resulting from an acute myocardial infarction , sudden cardiac death, death due to heart failure, death due to stroke, death due to cardiovascular procedures, death due to cardiovascular hemorrhage, and death due to other cardiovascular causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infraction</measure>
    <time_frame>7 days, 30 days, 1 year, and 3 years post-CABG</time_frame>
    <description>According to the 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials, including CABG-related MI, non CABG-related MI, silent MI and unknown type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>7 days, 30 days, 1 year, and 3 years post-CABG</time_frame>
    <description>According to the 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials, including ischemic, hemorrhagic and unknown type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat revascularization</measure>
    <time_frame>7 days, 30 days, 1 year, and 3 years post-CABG</time_frame>
    <description>According to the 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials, including any PCI and CABG.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>MACE Group</arm_group_label>
    <description>MACE Group includes the patients suffered from any component of MACE after RA-CABG until the latest follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-MACE Group</arm_group_label>
    <description>Non-MACE Group includes the patients freed from any component of MACE after RA-CABG until the latest follow-up.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients 18-year and above underwent RA-CABG from Jan. 2009 to Dec.2019 in one single&#xD;
        center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Underwent CABG using at least a radial artery grafts from Jan.2009 to Dec.2019. with&#xD;
             or without cardiopulmonary bypass , with or without concomitant procedure&#xD;
&#xD;
          -  Aged 18 and above at procedure&#xD;
&#xD;
          -  With any gender&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With unavailable medical records&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiang Zhao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yunpeng Zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruijin Hospital Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>September 4, 2021</last_update_submitted>
  <last_update_submitted_qc>September 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Qiang Zhao,MD</investigator_full_name>
    <investigator_title>Professor and Director, Department of Cardiovascular Surgery, Vice President, Ruijin Hospital</investigator_title>
  </responsible_party>
  <keyword>Risk Factors</keyword>
  <keyword>CABG</keyword>
  <keyword>Radial Artery</keyword>
  <keyword>MACE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

